Objective: To evaluate structural racism in the neonatal intensive care unit (NICU) by determining if differences in adverse social events occur by racialized groups.
Study Design: Retrospective cohort study of 3290 infants hospitalized in a single center NICU between 2017 and 2019 in the Racial and Ethnic Justice in Outcomes in Neonatal Intensive Care (REJOICE) study. Demographics and adverse social events including infant urine toxicology screening, child protective services (CPS) referrals, behavioral contracts, and security emergency response calls were collected from electronic medical records. Logistic regression models were fit to test the association of race/ethnicity and adverse social events, adjusting for length of stay. Racial/ethnic groups were compared with a White referent group.
Results: There were 205 families (6.2%) that experienced an adverse social event. Black families were more likely to have experienced a CPS referral and a urine toxicology screen (OR, 3.6; 95% CI, 2.2-6.1 and OR, 2.2; 95% CI, 1.4-3.5). American Indian and Alaskan Native families were also more likely to experience CPS referrals and urine toxicology screens (OR, 15.8; 95% CI, 6.9-36.0 an OR, 7.6; 95% CI, 3.4-17.2). Black families were more likely to experience behavioral contracts and security emergency response calls. Latinx families had a similar risk of adverse events, and Asian families were less likely to experience adverse events.
Conclusions: We found racial inequities in adverse social events in a single-center NICU. Investigation of generalizability is necessary to develop widespread strategies to address institutional and societal structural racism and to prevent adverse social events.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758992 | PMC |
http://dx.doi.org/10.1016/j.jpeds.2023.113499 | DOI Listing |
Sci Rep
January 2025
Institute for Disaster Management and Reconstruction, Sichuan University, No. 122, Section 1, Huanghe Middle Road, Chengdu, 610211, China.
In the early days of the urban pandemic, many cities had personal protective equipment (PPE) shortages, which adversely affected urban pandemic governance. Using the COVID-19 strategies employed in Wuhan as the pivotal case study, this study sought to determine effective strategies to optimize city PPE distribution. System dynamics modeling was employed to explore the influence of PPE allocation strategies on pandemic control measures.
View Article and Find Full Text PDFBMJ Open
January 2025
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
Objectives: To assess the therapeutic effects and safety of Tongxie Yaofang (TXYF) granules vs placebo as an alternative treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). We hypothesised that TXYF would improve clinical responses among patients with IBS-D.
Design: A randomised, double-blind, placebo-controlled, phase II, superiority trial.
Child Abuse Negl
January 2025
School of Nursing & Healthcare Leadership, University of Washington, Tacoma, WA, United States.
Backgrounds: Exposure to adverse childhood experiences (ACEs) is associated with adverse neurobiological, developmental, cognitive, behavioral, psychological, and social consequences among children and adolescents. Psychosocial interventions hold promise for mitigating the negative impacts of ACEs, but there is a lack of updated and comprehensive evidence summarizing their effects qualitatively and quantitatively.
Aims: We performed a systematic review and meta-analysis of existing evidence on the effectiveness of psychosocial interventions on children's outcomes, including internalizing and externalizing problems.
Reumatismo
January 2025
Unit of Dermatology, Department of Medicine and Aging Science, G. d'Annunzio University, Chieti.
Objective: Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.
Methods: An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!